Aeterna Zentaris Inc. (AEZS) recently announced that its oncology candidate, AEZS-108 (doxorubicin peptide conjugate) will be evaluated under US...(read more
Active traders and day traders have many stocks to choose from this Wednesday morning. We are tracking news and moves in shares of AEterna Zentaris, Inc. (NASDAQ: AEZS), Finisar, Inc. (NASDAQ: FNSR), JDS Uniphase Corporation (NASDAQ: JDSU), and O...
Many of those who purchased at $1.15 per share following my September 17th article have sent me inquiries about my current view on AEterna Zentaris (AEZS) and where to sell AEZS. AEZS is currently $1.54 per share, which represents nearly a 34% gain in the past 10 weeks. Some may have locked [...]